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ABSTRACT 
Objective: Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate associated with aging. BPH can cause lower urinary 
tract syndrome (LUTS). Medical therapy for patients with moderate and severe LUTS symptoms comprises α-1 adrenergic receptor antagonists. 
This study aimed to determine whether there are differences in the international prostate symptom score (IPSS) and maximal flow rate (Qmax
Methods: This study was a double-blind randomized clinical trial. Subjects were 50 men aged ≥ 50 y diagnosed with BPH with an IPSS ≥ 8 at the 
Gatot Soebroto Indonesian Army Hospital. The participants received either silodosin or tamsulosin. Their IPSS and Q
) of 
patients with BPH receiving either silodosin or tamsulosin over 12 w. 
max
Results: The initial median IPSS was 15 in the tamsulosin group and 17 in the silodosin group (P = 0.808). After 12 w of therapy, the median IPSS 
decreased to 9 in the tamsulosin group and 10 in the silodosin group (P = 0.186). The initial median Q
 were assessed at the initial 
assessment and after 4, 8, and 12 w of treatment. 
max was 10.1 ml/s in the tamsulosin group and 
10.9 ml/s in the silodosin group (P = 0.290). After 12 w of therapy, the median Qmax increased to 12.1 ml/s in the tamsulosin group and 11.9 ml/s in 
the silodosin group (P = 0.969). Although the differences between groups were not significant, the initial and 12-week IPSS and Qmax
Conclusion: There were no significant between-group differences in the IPSS or Q
 values differed 
significantly within each group. 
max after 12 w of therapy. However, both silodosin and tamsulosin 
produced significant differences between initial and 12-week assessments of IPSS and Qmax
Keywords: Benign prostate hyperplasia, Alpha-blocker, IPSS, Maximal flow rate 
. 
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INTRODUCTION 
Benign prostatic hyperplasia (BPH) prevalence in men increases 
with age. At 50 y old, 50%–75% of men will suffer from BPH. This 
proportion increases to 80% in men aged 70 y or more, and to 88%–
90% in men aged 81 y and over [1, 2]. The prevalence of BPH in 
Indonesia has not been reported. The prevalence in Cipto 
Mangunkusumo General Hospital from 1994 to 2013 was 3804 
patients with a mean age of 66.61 y [1]. 
Patients with BPH have symptoms of lower urinary tract syndrome 
(LUTS). LUTS symptoms are divided into obstructive, irritative, and 
postvoiding symptoms. Obstructive symptoms include a weak urine 
stream, interrupted voiding, straining to urinate, and retention of 
urine; irritative symptoms include polyuria, dysuria, urgency, and 
nocturia; and the postvoiding symptom is dribbling urine [1–3]. 
Platz reported in 2012 that the prevalence of moderate and severe 
LUTS was 41 and 19 cases per 1000 patients/year, respectively [4]. 
The international prostate symptom score (IPSS) is recommended 
as an ideal instrument for screening the severity of LUTS, the 
therapeutic response, and improvement in symptoms. Patients with 
moderate and severe LUTS (IPSS 8–35) require additional 
evaluations including a urodynamic test, uroflowmetry, and 
evaluation of postvoiding urinary retention [5]. 
Medical therapy with an α-1 adrenergic receptor antagonist (α1-AR) 
is usually given to patients with moderate and severe LUTS [1, 3, 6–
8]. These drugs inhibit smooth muscle contraction in the prostate, 
and thus decrease the resistance of the bladder neck and improve 
urethral tone. The first generation of α1-ARs used to treat patients 
with BPH were nonselective. Subsequently, selective α1-ARs 
including tamsulosin and naftopidil were developed. 
Recently, a more selective α1-AR, silodosin, was developed in Japan. 
Silodosin was confirmed to be 38 times more selective toward α1A 
adrenergic receptors than α1B adrenergic receptors [9, 10]. A phase 
III clinical trial found that silodosin improved the IPSS within the first 
2 w of usage [7], and another trial confirmed that the efficacy of 8 
mg/day silodosin was comparable to that of 0.2 mg/day tamsulosin 
[10]. Few trials have compared silodosin with tamsulosin in clinical 
practice [9]. The present study aimed to compare the efficacy of 8 
mg/day silodosin with that of 0.4 mg/day tamsulosin in patients with 
BPH with moderate–severe LUTS symptoms in a double blind 
randomized clinical trial. Because clinical use of silodosin was only 
recently initiated in Indonesia, this study was considered as a pioneer 
study of the efficacy of silodosin in BPH. 
MATERIALS AND METHODS 
This was a double-blind clinical trial that was conducted in the Urology 
Clinic, Gatot Subroto Central Army Hospital. Data were gathered from 
February 2017 to July 2017. The Faculty of Medicine, Universitas 
Indonesia Ethics Committee approved the study protocol (ethics 
clearance number 382/UN2. F1/ETIK/2017). Consecutive sampling 
was used in this study with a total sample size of 50 subjects who were 
divided into two groups. The inclusion criteria were men aged ≥ 50 y 
who were diagnosed with LUTS related to BPH, had an IPSS ≥ 8, a 
Qmax
Patients that fulfilled the inclusion criteria and had not been excluded 
from the Urology Clinic in Gatot Subroto Central Army Hospital were 
the ones who underwent a one-week washout from their previous 
therapy. When the LUTS symptoms appeared after one week, IPSS and 
uroflowmetry assessments were performed, after which patients were 
allocated to silodosin 8 mg/day or tamsulosin 0.4 mg/day using the 
double-blind procedure. Assessment of IPSS and Q
>4 and<15 ml/s, and who had agreed to complete the 12-week 
study. Patients with prostate cancer or who refused silodosin or 
tamsulosin were excluded from the study. To ensure blinding, a third 
party was assigned to allocate the treatment arm using similar sealed 
envelopes. Therefore, neither the investigators nor the patients knew 
which drug was given to the patients. 
max were performed 
after 4, 8, and 12 w of treatment. 
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The variables collected in this study were identity, age, IPSS, and 
uroflowmetry results. The data gathered are presented descriptively and 
analytically. Descriptive analysis was used for the subjects’ demographic 
characteristics including age, IPSS score, and uroflowmetry. The data are 
presented as mean ± standard deviation (SD) or as median (min–max) if 
the data were not normally distributed. 
We also compared the efficacy of silodosin and tamsulosin. Comparative 
analysis of IPSS and Qmax within each drug-treatment group were 
performed during the initial assessment, and after 4, 8, and 12 w of 
treatment. A repeated-measures analysis of variance with Bonferroni 
post hoc correction was employed if the data were normally distributed 
or could be log10 transformed. If the data were not normally distributed, 
Friedman’s test and the Wilcoxon post hoc test were employed. 
Analyses comparing the IPSS and Qmax for silodosin and tamsulosin 
were performed at the initial assessment and after 4, 8, and 12 w of 
treatment. A generalized linear model was employed if the data 
were normally distributed or the data were log10
Differences were deemed to be significant if P<0.05. The software 
employed in this study was the Statistical Package for the Social 
Sciences (SPSS) ver. 20 for Windows by IBM (address: New York, 
USA). Ethical issues that could arise in this study included patient 
confidentiality and drug-related adverse events. Patient medical 
records were considered confidential and the access to the 
medical records was limited to the investigators. At the beginning 
of the study, the subjects were informed about the potential 
adverse events that could occur, including ejaculatory disorders 
(retrograde ejaculation), increased risk of upper respiratory tract 
infection, and thirst. All subjects were also advised to mention any 
adverse events at every visit (4, 8, and 12 w) so that they could be 
recorded. 
 transformed. If the 
data were not normally distributed, a repeated-measures Mann–
Whitney test was used. 
RESULTS 
Fifty subjects participated in this clinical trial. Subjects were divided 
into tamsulosin and silodosin groups. The median age of subjects in 
the tamsulosin group was 61.8 (53–73) years and that of the 
silodosin group was 61.7 (53–72) years. The demographic 
characteristics of the subjects are listed in table 1. 
 
Table 1: Demographic and clinical characteristics of subjects 
 N Tamsulosin median (min–max) N Silodosin median (min–max) P 
Age 25 61 (53–73) 25 63 (53–72) 0.876 
Initial IPSS 25 15 (9–29) 25 17 (8–26) 0.808 
Initial Q 25 max 10.1 (4.1–13.4) 25 10.9 (1.9–19.8) 0.290 
IPSS = international prostate symptom score., In the tamsulosin group, there was a significant reduction in IPSS (P =<0.001) and a significant 
increase in Qmax
 
 (P =<0.001) between the initial and 12-week assessment (table 2). 
Table 2: Effect of tamsulosin on IPSS and uroflowmetry 
  N Median (min–max) P 
IPSS Initial 25 15 (9–29) <0.001 
4 w 25 11 (8–22)  
8 w 25 9 (7–17)  
12 w 25 9 (7–15)  
Initial vs 12 w IPSS    <0.001 
Q
(ml/s) 
max Initial 25 10.1 (4.1–13.4) <0.001 
4 w 25 11.5 (5.7–14.5)  
8 w 25 11.8 (6.2–14.7)  
12 w 25 12.1 (7.6–13.7)  
Initial vs 12 w Q  max   <0.001 
IPSS = international prostate symptom score., In the silodosin group, there was a significant reduction in IPSS (P =<0.001) and a significant increase 
in Qmax
 
 (P =<0.001) between the initial and 12-week assessment (table 3) 
Table 3: Effect of silodosin on IPSS and uroflowmetry 
  N mean±SD P 
IPSS Initial 25 16.8±5 <0.001 
4 w 25 13.3±3.7  
8 w 25 11±2.9  
12 w 25 10.2±2.3  























IPSS = international prostate symptom score., We also compared the effects of tamsulosin and silodosin. The analysis showed that there were no significant 
differences in IPSS and uroflowmetry between the tamsulosin and silodosin groups at the initial assessment or after 4, 8, or 12 w of treatment (table 4). 
 
Table 4: Comparison of IPSS and uroflowmetry between tamsulosin and silodosin groups 
  Tamsulosin median (min–max) Silodosin median (min–max) P 
IPSS Initial 15 (9–29) 17 (8–26) 0.808 
 4 w 11 (8–22) 14 (8–19) 0.483 
 8 w 9 (7–17) 11 (7–17) 0.190 
 12 w 9 (7–15) 10 (7–15) 0.186 
Qmax Initial  (ml/s) 10.1 (4.1–13.4) 10.9 (1.9–19.8) 0.290 
4 w 11.5 (5.7–14.5) 11.6 (5.5–14.6) 0.432 
8 w 11.8 (6.2–14.7) 12.4 (7.8–14.9) 0.382 
12 w 12.1 (7.6–13.7) 11.9 (8–13.8) 0.969 
IPSS = international prostate symptom score. 
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Many α1-ARs, including tamsulosin, prazosin, terazosin, and alfuzosin, 
have been used to treat BPH associated with moderate to severe LUTS 
[11] and have been clinically demonstrated to improve LUTS symptoms 
in BPH. The first-generation α1-ARs frequently cause the side effect of 
orthostatic hypotension [10], and so new α1-ARs with fewer side effects 
are needed. Silodosin, a new indolin derivative, is a new-generation α1-
AR developed in Japan during the 1990s [12]. 
The present study showed a significant decrease in IPSS and increase in 
Qmax between the initial assessment and the 12-week follow-up for 
both tamsulosin and silodosin groups. The median IPSS of the 
tamsulosin group was reduced to 7 and that of the silodosin group to 6 
after 12 w of treatment, although the difference between groups was not 
significant. The median Qmax was significantly increased by 1 ml/s in 
the silodosin group and 2 ml/s in the tamsulosin group after 12 w of 
drug administration, although again, there was no significant difference 
between silodosin and tamsulosin groups. 
Several studies have compared the efficacy of tamsulosin and 
silodosin in BPH. Chapple et al. showed a reduction of IPSS in 
tamsulosin and silodosin groups compared with a placebo group 
[13], although there was no significant difference in IPSS between 
the treatment groups at the end of the study. Natarajan et al. showed 
that there was no significant difference between groups treated with 
silodosin and tamsulosin after 12 w of administration [5]. Takeshita 
et al. also showed a decrease in IPSS after 4 w of tamsulosin and 
silodosin administration, and there was no significant difference 
between the groups [14]. Pande et al. also showed that there was no 
significant difference in IPSS between tamsulosin and silodosin 
groups at any follow-up [15]. A clinical trial by Manohar et al. that 
compared tamsulosin, alfuzosin, and silodosin also showed that 
there was no significant difference in IPSS between groups after 12 
w of administration. Therefore, the findings of the present study are 
consistent with many reports that there is no significant difference 
between the decrease in IPSS induced by treatment with tamsulosin 
or silodosin for up to 12 w [5, 13–16]. 
However, the findings for Qmax are less consistent. Chapple et al. reported 
that both tamsulosin and silodosin induced an increase in Qmax between 
the initial assessment and after 12 w of treatment, and that there was no 
significant difference between the drugs [13]. However, Takeshita et al. 
found that the only improvement in Qmax occurred within the first month 
of silodosin administration, and that tamsulosin had no effect on Qmax 
[14], while Pande et al. reported no improvement of Qmax between initial 
and 12-week assessments [15]. A clinical trial by Manohar et al. found 
that 1 w of administration of silodosin had a greater effect on maximal 
flow compared with 1 w of tamsulosin or alfuzosin [16]. The Qmax 
CONCLUSION 
was 
also increased after 4 and 12 w of treatment, although the difference 
between silodosin, tamsulosin, and alfuzosin groups was not significant. 
The findings of the present study are consistent with those of Chapple et 
al. and Manohar et al. 
This study has several limitations. Ultrasound-guided measurement of 
prostate volume before and after drug administration was not 
performed in this study because of limited resources. The lack of 
resources also limited the number of subjects, which affected the study 
because the complication rate associated with drug administration could 
not be assessed. The ethnic profile of the subjects remains to be 
investigated. However, this study was the first clinical trial to compare 
silodosin and tamsulosin efficacy for treating BPH in Indonesian patients 
and could be a reference study for further research in Indonesia. 
Silodosin had similar efficacy to tamsulosin for decreasing IPSS and 
increasing Qmax
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